Louis Garguilo

ARTICLES BY LOUIS

  • 11/16/2026

    In Japan, a practicing medical doctor becoming an entrepreneur and the CEO of a biotech start-up is still relatively rare. Rarer is when Yusaku Katada, M.D., Ph.D., founded Restore Vision, and selected a U.S. CDMO to usher his program through development and manufacturing. That program is a visual-restoration, gene-therapy technology for inherited retinal disease ("IRD"). Regarding that U.S.-based CDMO selection, there’s an ironic twist to along with this interesting back story.

  • 11/13/2026

    The U.S. government may be relenting on WuXi AppTec. At the least, it’s walked a step backwards in its attempt to target the CDMO, reports Chief Editor Louis Garguilo. The Department of Defense (DoD) has removed WuXi AppTec from its list of Chinese military companies. Here's analysis of what happened, and what might happen next.

  • 11/12/2026

    Heather Walters of CRB spends her time thinking about effective business and industrial sustainability and resource conservation. Meanwhile, Chief Editor Louis Garguilo maintains a position near the bottom of the list of interested parties. It made for great conversation. Uncovered were the current realities of sustainability in manufacturing facilities, and the importance of two components: electrification and digital twins.

  • 11/10/2026

    A CDMO employs accomplished professionals, operates modern facilities, and still frustrates the heck out of you. Accumulated talent and capabilities are impressive, but closer examination reveals the problem lies between the lines of the CDMO’s work demarcations. Instead, you need your CDMO to operate as a constellation of unified skills. Chief Editor Louis Garguilo explores this "holistic pattern of work that forms an interconnected organization, and presents a clear picture of management and culture."

  • 11/4/2026

    Consultants tell Chief Editor Louis Garguilo that too often those who should know better – from executives to project managers – overestimate their ability to manage CMC activities.

    That’s surprising, and suggests a fundamental - but detailed - refresher of the key positioning of CMC is in order as we approach yearend.

  • 10/30/2026

    A supply-chain reformer, book author, strategic advisor to drug sponsors of all sizes, investors, and policymakers, says, “The non-clinical supply chain as the foundation of reliable commercial supply receives too little attention from prospective clinical trial sponsors. We could be doing a heck of a lot better." A discussion between Hedley Rees and our Chief Editor, Louis Garguilo.

  • 10/26/2026

    The biopharmaceutical's “Valley of Death” is entered through a desert of dwindling funding. Chief Editor Louis Garguilo talks with two consultants on avoiding financial failure when outsourcing development and manufacturing. The many contributing factors for failure may have a common denominator: Project Management is an overlooked financial savior.

  • 10/19/2026

    Subpar customer service at CDMOs is no longer something sponsors tolerate; there’s enough competition where they can move on. The other side of the coin is how difficult sponsors sink to the bottom of CDMO priorities; providers also have options. Here's an analysis less about technical components of outsourcing, and more on mutual satisfactions from working together to fulfill contractual arrangements and missions.

  • 10/13/2026

    The FDA calls on your CDMO; inspectors are fortified by data in AI models, and appear practically clairvoyant. “It won’t be like the ‘old days,’” says David Grote of GrayMatters Partners, an organization that advises on quality systems and inspection readiness. The agency earlier rolled out Elsa, an AI-enable data architecture. Now its added an impressive HALO - Harmonized AI & Lifecycle Operations for Data.

  • 10/8/2026

    A number of patients report receiving half a pill in a blister pack of their prescribed medicine. The initial sponsor reaction is to place the problem at an external partner’s production or packaging line. But overall responsibility lies with the sponsor, and the true extent of the problem is hard to detect. Enter AI. Experienced pharma quality expert Damiano Dragone believes AI combined with professionals throughout the supply chain can join in a new “logic and creativity" to improve our industry on behalf of patients.

louis-g-photo-edited

Louis Garguilo



Louis Garguilo is chief editor of Outsourced Pharma, and is considered a leading authority on the art and science of drug development and manufacturing outsourcing. He studied public relations and journalism at Syracuse University (and holds a Master’s in English). His widely read editorials are based on in-depth analysis and interviews with industry executives and professionals. Editorials are written in an engaging and unique style that guide readers through the macro aspects and subtle nuances of outsourcing, and working with contract development and manufacturing organizations (CDMOs). Garguilo also serves as moderator for the various Outsourced Pharma Live webinars held throughout the year.

Prior to joining Outsourced Pharma in 2014, Garguilo spent a decade at a global pharmaceutical contract research, development and manufacturing organization, leaving the industry after attaining the role of vice president, business development and marketing. Additionally, he has served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; as chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and communications consultant.